Effects of Mammalian Thioredoxin Reductase Inhibitors.
Reactive oxygen species
Redox signaling
Selenoprotein
Thioredoxin reductase
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
9
8
2020
medline:
26
2
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
The mammalian thioredoxin system is driven by NADPH through the activities of isoforms of the selenoprotein thioredoxin reductase (TXNRD, TrxR), which in turn help to keep thioredoxins (TXN, Trx) and further downstream targets reduced. Due to a wide range of functions in antioxidant defense, cell proliferation, and redox signaling, strong cellular aberrations are seen upon the targeting of TrxR enzymes by inhibitors. However, such inhibition can nonetheless have rather unexpected consequences. Accumulating data suggest that inhibition of TrxR in normal cells typically yields a paradoxical effect of increased antioxidant defense, with metabolic pathway reprogramming, increased cellular proliferation, and altered cellular differentiation patterns. Conversely, inhibition of TrxR in cancer cells can yield excessive levels of reactive oxygen species (ROS) resulting in cell death and thus anticancer efficacy. The observed increases in antioxidant capacity upon inhibition of TrxR in normal cells are in part dependent upon activation of the Nrf2 transcription factor, while exaggerated ROS levels in cancer cells can be explained by a non-oncogene addiction of cancer cells to TrxR1 due to their increased endogenous production of ROS. These separate consequences of TrxR inhibition can be utilized therapeutically. Importantly, however, a thorough knowledge of the molecular mechanisms underlying effects triggered by TrxR inhibition is crucial for the understanding of therapy outcomes after use of such inhibitors. The mammalian thioredoxin system is driven by thioredoxin reductases (TXNRD, TrxR), which keeps thioredoxins (TXN, Trx) and further downstream targets reduced. In normal cells, inhibition of TrxR yields a paradoxical effect of increased antioxidant defense upon activation of the Nrf2 transcription factor. In cancer cells, however, inhibition of TrxR yields excessive reactive oxygen species (ROS) levels resulting in cell death and thus anticancer efficacy, which can be explained by a non-oncogene addiction of cancer cells to TrxR1 due to their increased endogenous production of ROS. These separate consequences of TrxR inhibition can be utilized therapeutically.
Identifiants
pubmed: 32767140
doi: 10.1007/164_2020_393
doi:
Substances chimiques
Antioxidants
0
Reactive Oxygen Species
0
Thioredoxin-Disulfide Reductase
EC 1.8.1.9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-309Références
Andersson M, Holmgren A, Spyrou G (1996) NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity. J Biol Chem 271:10116–10120
pubmed: 8626570
Anestål K, Arnér ESJ (2003) Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278:15966–15972
pubmed: 12574159
Anestål K, Prast-Nielsen S, Cenas N, Arnér ESJ (2008) Cell death by SecTRAPs – thioredoxin reductase as a prooxidant killer of cells. PLoS One 3:e1846
pubmed: 18382651
pmcid: 2268967
Arnér ESJ (2009) Focus on mammalian thioredoxin reductases – important selenoproteins with versatile functions. Biochim Biophys Acta 1790:495–526
pubmed: 19364476
Arnér ESJ (2010) Selenoproteins-what unique properties can arise with selenocysteine in place of cysteine? Exp Cell Res 316:1296–1303
pubmed: 20206159
Arner ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102–6109
pubmed: 11012661
Arnér ESJ, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16:420–426
pubmed: 17092741
Arnér ESJ, Nordberg J, Holmgren A (1996) Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Commun 225:268–274
pubmed: 8769129
Arscott LD, Gromer S, Schirmer RH, Becker K, Williams CH Jr (1997) The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc Natl Acad Sci U S A 94:3621–3626
pubmed: 9108027
pmcid: 20490
Backman E, Bergh AC, Lagerdahl I, Rydberg B, Sundstrom C, Tobin G, Rosenquist R, Linderholm M, Rosen A (2007) Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro. Haematologica 92:1495–1504
pubmed: 18024398
Bacon JR, Plumb GW, Howie AF, Beckett GJ, Wang W, Bao Y (2007) Dual action of sulforaphane in the regulation of thioredoxin reductase and thioredoxin in human HepG2 and Caco-2 cells. J Agric Food Chem 55:1170–1176
pubmed: 17300148
Becker K, Gromer S, Schirmer RH, Müller S (2000) Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 267:6118–6125
pubmed: 11012663
Bellisola G, Fracasso G, Ippoliti R, Menestrina G, Rosen A, Solda S, Udali S, Tomazzolli R, Tridente G, Colombatti M (2004) Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. Biochem Pharmacol 67:1721–1731
pubmed: 15081871
Biterova EI, Turanov AA, Gladyshev VN, Barycki JJ (2005) Crystal structures of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of the reaction mechanism. Proc Natl Acad Sci U S A 102:15018–15023
pubmed: 16217027
pmcid: 1257698
Bondareva AA, Capecchi MR, Iverson SV, Li Y, Lopez NI, Lucas O, Merrill GF, Prigge JR, Siders AM, Wakamiya M, Wallin SL, Schmidt EE (2007) Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome. Free Radic Biol Med 43:911–923
pubmed: 17697936
pmcid: 2099259
Brigelius-Flohe R (2008) Selenium compounds and selenoproteins in cancer. Chem Biodivers 5:389–395
pubmed: 18357548
Brigelius-Flohe R, Banning A (2006) Part of the series: from dietary antioxidants to regulators in cellular signaling and gene regulation. Sulforaphane and selenium, partners in adaptive response and prevention of cancer. Free Radic Res 40:775–787
pubmed: 17015256
Brigelius-Flohe R, Flohe L (2011) Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal 15:2335–2381
pubmed: 21194351
pmcid: 3166203
Brown KK, Eriksson SE, Arner ES, Hampton MB (2008) Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol Med 45:494–502
pubmed: 18501718
Busker S, Qian W, Haraldsson M, Espinosa B, Johansson L, Attarha S, Kolosenko I, Liu J, Dagnell M, Grander D, Arner ESJ, Tamm KP, Page BDG (2020) Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death. Sci Adv 6:eaax7945
pubmed: 32219156
pmcid: 7083616
Cai W, Zhang L, Song Y, Wang B, Zhang B, Cui X, Hu G, Liu Y, Wu J, Fang J (2012) Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 52:257–265
pubmed: 22064364
Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A (2008) Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol Chem 283:11913–11923
pubmed: 18321861
Casini A, Gabbiani C, Sorrentino F, Rigobello MP, Bindoli A, Geldbach TJ, Marrone A, Re N, Hartinger CG, Dyson PJ, Messori L (2008) Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J Med Chem 51:6773–6781
pubmed: 18834187
Cebula M, Moolla N, Capovilla A, Arner ES (2013) The rare TXNRD1_v3 ("v3") splice variant of human thioredoxin reductase 1 protein is targeted to membrane rafts by N-acylation and induces filopodia independently of its redox active site integrity. J Biol Chem 288:10002–10011
pubmed: 23413027
pmcid: 3617239
Cebula M, Schmidt EE, Arner ES (2015) TrxR1 as a potent regulator of the Nrf2-Keap1 response system. Antioxid Redox Signal 23:823–853
pubmed: 26058897
pmcid: 4589110
Cenas N, Nivinskas H, Anusevicius Z, Sarlauskas J, Lederer F, Arnér ESJ (2004) Interactions of quinones with thioredoxin reductase – a challenge to the antioxidant role of the mammalian selenoprotein. J Biol Chem 279:2583–2592
pubmed: 14604985
Cheng Q, Sandalova T, Lindqvist Y, Arnér ESJ (2009) Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284:3998–4008
pubmed: 19054767
Chew EH, Lu J, Bradshaw TD, Holmgren A (2008) Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22:2072–2083
pubmed: 18180330
Chew EH, Nagle AA, Zhang Y, Scarmagnani S, Palaniappan P, Bradshaw TD, Holmgren A, Westwell AD (2010) Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med 48:98–111
pubmed: 19837157
Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M (2004) Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24:9414–9423
pubmed: 15485910
pmcid: 522221
Copple IM, Goldring CE, Kitteringham NR, Park BK (2008) The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 246:24–33
pubmed: 18083283
Cox AG, Brown KK, Arner ES, Hampton MB (2008) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76:1097–1109
pubmed: 18789312
Dagnell M, Frijhoff J, Pader I, Augsten M, Boivin B, Xu J, Mandal PK, Tonks NK, Hellberg C, Conrad M, Arner ES, Ostman A (2013a) Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-beta receptor tyrosine kinase signaling. Proc Natl Acad Sci U S A 110:13398–13403
pubmed: 23901112
pmcid: 3746926
Dagnell M, Frijhoff J, Pader I, Augsten M, Boivin B, Xu J, Mandal PK, Tonks NK, Hellberg C, Conrad M, Arnér ESJ, Östman A (2013b) Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGFβ-receptor tyrosine kinase signaling. Proc Natl Acad Sci U S A 110:13398–13403
pubmed: 23901112
pmcid: 3746926
Dagnell M, Pace PE, Cheng Q, Frijhoff J, Ostman A, Arner ESJ, Hampton MB, Winterbourn CC (2017) Thioredoxin reductase 1 and NADPH directly protect protein tyrosine phosphatase 1B from inactivation during H2O2 exposure. J Biol Chem 292:14371–14380
pubmed: 28684416
pmcid: 5582832
Dagnell M, Schmidt EE, Arner ESJ (2018) The A to Z of modulated cell patterning by mammalian thioredoxin reductases. Free Radic Biol Med 115:484–496
pubmed: 29278740
Damdimopoulos AE, Miranda-Vizuete A, Treuter E, Gustafsson JÅ, Spyrou G (2004) An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling. J Biol Chem 279:38721–38729
pubmed: 15199063
Damdimopoulou PE, Miranda-Vizuete A, Arner ESJ, Gustafsson J-A, Damdimopoulos AE (2009) The human thioredoxin reductase-1 splice variant TXNRD1_v3 is an atypical inducer of cytoplasmic filaments and cell membrane filopodia. BBA-Mol Cell Res 1793:1588–1596
Dammeyer P, Damdimopoulos AE, Nordman T, Jimenez A, Miranda-Vizuete A, Arner ES (2008) Induction of cell membrane protrusions by the N-terminal glutaredoxin domain of a rare splice variant of human thioredoxin reductase 1. J Biol Chem 283:2814–2821
pubmed: 18042542
Doka E, Pader I, Biro A, Johansson K, Cheng Q, Ballago K, Prigge JR, Pastor-Flores D, Dick TP, Schmidt EE, Arner ES, Nagy P (2016) A novel persulfide detection method reveals protein persulfide- and polysulfide-reducing functions of thioredoxin and glutathione systems. Sci Adv 2:e1500968
pubmed: 26844296
pmcid: 4737208
Doka E, Ida T, Dagnell M, Abiko Y, Luong NC, Balog N, Takata T, Espinosa B, Nishimura A, Cheng Q, Funato Y, Miki H, Fukuto JM, Prigge JR, Schmidt EE, Arner ESJ, Kumagai Y, Akaike T, Nagy P (2020) Control of protein function through oxidation and reduction of persulfidated states. Sci Adv 6:eaax8358
pubmed: 31911946
pmcid: 6938701
Du Y, Zhang H, Zhang X, Lu J, Holmgren A (2013) Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system. J Biol Chem 288:32241–32247
pubmed: 24062305
pmcid: 3820862
Eckenroth B, Harris K, Turanov AA, Gladyshev VN, Raines RT, Hondal RJ (2006) Semisynthesis and characterization of mammalian thioredoxin reductase. Biochemistry 45:5158–5170
pubmed: 16618105
pmcid: 2570056
Eckenroth BE, Lacey BM, Lothrop AP, Harris KM, Hondal RJ (2007a) Investigation of the C-terminal redox center of high-Mr thioredoxin reductase by protein engineering and semisynthesis. Biochemistry 46:9472–9483
pubmed: 17661444
pmcid: 3682222
Eckenroth BE, Rould MA, Hondal RJ, Everse SJ (2007b) Structural and biochemical studies reveal differences in the catalytic mechanisms of mammalian and Drosophila melanogaster thioredoxin reductases. Biochemistry 46:4694–4705
pubmed: 17385893
pmcid: 3687216
Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ES (2009) High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med 47:1661–1671
pubmed: 19766715
Espinosa B, Arner ESJ (2019) Thioredoxin-related protein of 14 kDa as a modulator of redox signalling pathways. Br J Pharmacol 176:544–553
pubmed: 30129655
Fang J, Lu J, Holmgren A (2005) Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280:25284–25290
pubmed: 15879598
Felberbaum-Corti M, Morel E, Cavalli V, Vilbois F, Gruenberg J (2007) The redox sensor TXNL1 plays a regulatory role in fluid phase endocytosis. PLoS One 2:e1144
pubmed: 17987124
pmcid: 2043495
Finkel T (2000) Redox-dependent signal transduction. FEBS Lett 476:52–54
pubmed: 10878249
Finkel T (2011) Signal transduction by reactive oxygen species. J Cell Biol 194:7–15
pubmed: 21746850
pmcid: 3135394
Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454
pubmed: 18511445
Fritz-Wolf K, Urig S, Becker K (2007) The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J Mol Biol 370:116–127
pubmed: 17512005
Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12:829–846
pubmed: 24113830
Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G (2013) Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med 65:750–764
pubmed: 23820265
Gencheva R, Cheng Q, Arner ESJ (2018) Efficient selenocysteine-dependent reduction of toxoflavin by mammalian thioredoxin reductase. Biochim Biophys Acta Gen Subj 1862:2511–2517
Ghosh S, Mukherjee S, Choudhury S, Gupta P, Adhikary A, Baral R, Chattopadhyay S (2015) Reactive oxygen species in the tumor niche triggers altered activation of macrophages and immunosuppression: role of fluoxetine. Cell Signal 27:1398–1412
pubmed: 25819340
Gladyshev VN, Jeang K-T, Stadtman TC (1996) Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A 93:6146–6151
pubmed: 8650234
pmcid: 39204
Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12:931–947
pubmed: 24287781
Gromer S, Merkle H, Schirmer RH, Becker K (2002) Human placenta thioredoxin reductase: preparation and inhibitor studies. Methods Enzymol 347:382–394
pubmed: 11898429
Gromer S, Urig S, Becker K (2004) The thioredoxin system – from science to clinic. Med Res Rev 24:40–89
pubmed: 14595672
Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Brustle A, Molyneux SD, Mason JM, Li WY, Yamamoto K, Wakeham A, Berman HK, Khokha R, Done SJ, Kavanagh TJ, Lam CW, Mak TW (2015) Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27:211–222
pubmed: 25620030
pmcid: 25620030
Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A (2006) Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281:10691–10697
pubmed: 16481328
Hatfield DL, Yoo MH, Carlson BA, Gladyshev VN (2009) Selenoproteins that function in cancer prevention and promotion. Biochim Biophys Acta 1790:1541–1545
Hedstrom E, Eriksson S, Zawacka-Pankau J, Arner ES, Selivanova G (2009) p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle 8:3576–3583
Higgins LG, Hayes JD (2011) The cap'n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. Chem Biol Interact 192:37–45
pubmed: 20932822
Holmstrom KM, Finkel T (2014) Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 15:411–421
pubmed: 24854789
Hori K, Hirashima M, Ueno M, Matsuda M, Waga S, Tsurufuji S, Yodoi J (1993) Regulation of eosinophil migration by adult T cell leukemia-derived factor. J Immunol 151:5624–5630
pubmed: 8228251
Hu Y, Urig S, Koncarevic S, Wu X, Fischer M, Rahlfs S, Mersch-Sundermann V, Becker K (2007) Glutathione- and thioredoxin-related enzymes are modulated by sulfur-containing chemopreventive agents. Biol Chem 388:1069–1081
pubmed: 17937621
Huang J, Hua W, Li J, Hua Z (2015) Molecular docking to explore the possible binding mode of potential inhibitors of thioredoxin glutathione reductase. Mol Med Rep 12:5787–5795
pubmed: 26239395
pmcid: 4581810
Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, Roveri A, Peng X, Porto Freitas F, Seibt T, Mehr L, Aichler M, Walch A, Lamp D, Jastroch M, Miyamoto S, Wurst W, Ursini F, Arner ESJ, Fradejas-Villar N, Schweizer U, Zischka H, Friedmann Angeli JP, Conrad M (2017) Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell 172:409–422.
Iverson SV, Eriksson S, Xu J, Prigge JR, Talago EA, Meade TA, Meade ES, Capecchi MR, Arner ES, Schmidt EE (2013) A Txnrd1-dependent metabolic switch alters hepatic lipogenesis, glycogen storage, and detoxification. Free Radic Biol Med 63:369–380
pubmed: 23743293
Jakubikova J, Sedlak J, Bod'o J, Bao Y (2006) Effect of isothiocyanates on nuclear accumulation of NF-kappaB, Nrf2, and thioredoxin in caco-2 cells. J Agric Food Chem 54:1656–1662
pubmed: 16506816
Jeong W, Yoon HW, Lee SR, Rhee SG (2004) Identification and characterization of TRP14, a thioredoxin-related protein of 14 kDa. New insights into the specificity of thioredoxin function. J Biol Chem 279:3142–3150
pubmed: 14607844
Jimenez A, Oko R, Gustafsson JA, Spyrou G, Pelto-Huikko M, Miranda-Vizuete A (2002) Cloning, expression and characterization of mouse spermatid specific thioredoxin-1 gene and protein. Mol Hum Reprod 8:710–718
pubmed: 12149401
Jimenez A, Zu W, Rawe VY, Pelto-Huikko M, Flickinger CJ, Sutovsky P, Gustafsson JA, Oko R, Miranda-Vizuete A (2004) Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis. J Biol Chem 279:34971–34982
pubmed: 15181017
Jimenez A, Pelto-Huikko M, Gustafsson JA, Miranda-Vizuete A (2006) Characterization of human thioredoxin-like-1: potential involvement in the cellular response against glucose deprivation. FEBS Lett 580:960–967
pubmed: 16438969
Johansson C, Lillig CH, Holmgren A (2004) Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. J Biol Chem 279:7537–7543
pubmed: 14676218
Johansson L, Gafvelin G, Arnér ESJ (2005) Selenocysteine in proteins – properties and biotechnological use. Biochim Biophys Acta 1726:1–13
pubmed: 15967579
Johansson K, Cebula M, Rengby O, Dreij K, Carlstrom KE, Sigmundsson K, Piehl F, Arner ES (2017) Cross talk in HEK293 cells between Nrf2, HIF, and NF-kappaB activities upon challenges with redox therapeutics characterized with single-cell resolution. Antioxid Redox Signal 26:229–246
Kipp AP, Deubel S, Arner ESJ, Johansson K (2017) Time- and cell-resolved dynamics of redox-sensitive Nrf2, HIF and NF-kappaB activities in 3D spheroids enriched for cancer stem cells. Redox Biol 12:403–409
pubmed: 28319891
pmcid: 5357678
Krishnamurthy D, Karver MR, Fiorillo E, Orru V, Stanford SM, Bottini N, Barrios AM (2008) Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study. J Med Chem 51:4790–4795
pubmed: 18605719
Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN (2003) Characterization of mammalian selenoproteomes. Science 300:1439–1443
pubmed: 12775843
Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, Williams DL (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4:e206
pubmed: 17579510
pmcid: 1892040
Lea WA, Jadhav A, Rai G, Sayed AA, Cass CL, Inglese J, Williams DL, Austin CP, Simeonov A (2008) A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Assay Drug Dev Technol 6:551–555
pubmed: 18665782
pmcid: 2669305
Lee KK, Murakawa M, Takahashi S, Tsubuki S, Kawashima S, Sakamaki K, Yonehara S (1998) Purification, molecular cloning, and characterization of TRP32, a novel thioredoxin-related mammalian protein of 32 kDa. J Biol Chem 273:19160–19166
pubmed: 9668102
Lee SR, Kim JR, Kwon KS, Yoon HW, Levine RL, Ginsburg A, Rhee SG (1999) Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem 274:4722–4734
pubmed: 9988709
Lee SR, Bar-Noy S, Kwon J, Levine RL, Stadtman TC, Rhee SG (2000) Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci U S A 97:2521–2526
pubmed: 10688911
pmcid: 15961
Lee SB, Cha KH, Selenge D, Solongo A, Nho CW (2007) The chemopreventive effect of taxifolin is exerted through ARE-dependent gene regulation. Biol Pharm Bull 30:1074–1079
pubmed: 17541156
Lei XG, Zhu JH, Cheng WH, Bao Y, Ho YS, Reddi AR, Holmgren A, Arner ES (2016) Paradoxical roles of antioxidant enzymes: basic mechanisms and health implications. Physiol Rev 96:307–364
pubmed: 26681794
Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23:2425–2433
pubmed: 12894524
Liu Z, Du ZY, Huang ZS, Lee KS, Gu LQ (2008a) Inhibition of thioredoxin reductase by curcumin analogs. Biosci Biotechnol Biochem 72:2214–2218
pubmed: 18685195
Liu Z, Huang S, Li M, Huang Z, Lee KS, Gu L (2008b) Inhibition of thioredoxin reductase by mansonone F analogues: implications for anticancer activity. Chem Biol Interact 177:48–57
pubmed: 18822278
Locy ML, Rogers LK, Prigge JR, Schmidt EE, Arner ES, Tipple TE (2012) Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells: implications for oxidant-induced lung injury. Antioxid Redox Signal 17:1407–1416
pubmed: 22607006
pmcid: 3437047
Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A (2006) Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66:4410–4418
pubmed: 16618767
Lu J, Chew EH, Holmgren A (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104:12288–12293
pubmed: 17640917
pmcid: 1940330
Lundström-Ljung J, Birnbach U, Rupp K, Soling HD, Holmgren A (1995) Two resident ER-proteins, CaBP1 and CaBP2, with thioredoxin domains, are substrates for thioredoxin reductase: comparison with protein disulfide isomerase. FEBS Lett 357:305–308
pubmed: 7835433
Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823–837
pubmed: 19269363
pmcid: 2894612
Maggioli G, Silveira F, Martin-Alonso JM, Salinas G, Carmona C, Parra F (2011) A recombinant thioredoxin-glutathione reductase from Fasciola hepatica induces a protective response in rabbits. Exp Parasitol 129:323–330
pubmed: 21985914
Manda G, Isvoranu G, Comanescu MV, Manea A, Debelec Butuner B, Korkmaz KS (2015) The redox biology network in cancer pathophysiology and therapeutics. Redox Biol 5:347–357
pubmed: 26122399
pmcid: 4501561
Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H, Bornkamm GW, Conrad M (2010) Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 70:9505–9514
pubmed: 21045148
Martin JL (1995) Thioredoxin-a fold for all reasons. Structure 3:245–250
pubmed: 7788290
Martinez-Gonzalez JJ, Guevara-Flores A, Rendon JL, Arenal IPD (2015) Auranofin-induced oxidative stress causes redistribution of the glutathione pool in Taenia crassiceps cysticerci. Mol Biochem Parasitol 201:16–25
pubmed: 26024834
Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42:872–881
pubmed: 17320769
May JM, Mendiratta S, Hill KE, Burk RF (1997) Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem 272:22607–22610
pubmed: 9278416
Miranda-Vizuete A, Damdimopoulos AE, Pedrajas JR, Gustafsson JA, Spyrou G (1999) Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur J Biochem 261:405–412
pubmed: 10215850
Miranda-Vizuete A, Sadek CM, Jimenez A, Krause WJ, Sutovsky P, Oko R (2004) The mammalian testis-specific thioredoxin system. Antioxid Redox Signal 6:25–40
pubmed: 14713334
Mitsuishi Y, Motohashi H, Yamamoto M (2012) The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2:200
pubmed: 23272301
pmcid: 3530133
Mougiakakos D, Okita R, Ando T, Durr C, Gadiot J, Ichikawa J, Zeiser R, Blank C, Johansson CC, Kiessling R (2012) High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis. J Mol Med (Berl) 90:935–944
Nalvarte I, Damdimopoulos AE, Spyrou G (2004) Human mitochondrial thioredoxin reductase reduces cytochrome c and confers resistance to complex III inhibition. Free Radic Biol Med 36:1270–1278
pubmed: 15110392
Nordberg J, Arnér ESJ (2001) Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31:1287–1312
pubmed: 11728801
Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D, Bouillaguet S, Sano H, Lewis JB, Wataha JC (2006) Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol In Vitro 20:882–890
pubmed: 16510263
Osborne SA, Tonissen KF (2001) Genomic organisation and alternative splicing of mouse and human thioredoxin reductase 1 genes. BMC Genomics 2:10
pubmed: 11737861
pmcid: 60534
Osburn WO, Kensler TW (2008) Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 659:31–39
pubmed: 18164232
Otero L, Bonilla M, Protasio AV, Fernandez C, Gladyshev VN, Salinas G (2010) Thioredoxin and glutathione systems differ in parasitic and free-living platyhelminths. BMC Genomics 11:237
pubmed: 20385027
pmcid: 2873472
Pader I, Sengupta R, Cebula M, Xu J, Lundberg JO, Holmgren A, Johansson K, Arner ES (2014) Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase. Proc Natl Acad Sci U S A 111:6964–6969
pubmed: 24778250
pmcid: 4024855
Pasquet V, Bisio H, Lopez GV, Romanelli-Cedrez L, Bonilla M, Saldana J, Salinas G (2015) Inhibition of tapeworm thioredoxin and glutathione pathways by an oxadiazole N-oxide leads to reduced mesocestoides vogae infection burden in mice. Molecules 20:11793–11807
pubmed: 26132905
pmcid: 6332120
Pekkari K, Holmgren A (2004) Truncated thioredoxin: physiological functions and mechanism. Antioxid Redox Signal 6:53–61
pubmed: 14713335
Pekkari K, Goodarzi MT, Scheynius A, Holmgren A, Avila-Carino J (2005) Truncated thioredoxin (Trx80) induces differentiation of human CD14+ monocytes into a novel cell type (TAMs) via activation of the MAP kinases p38, ERK, and JNK. Blood 105:1598–1605
pubmed: 15494431
Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arner ES, Wiman KG (2013) APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis 4:e881
pubmed: 24157875
pmcid: 3920950
Peng X, Gimenez-Cassina A, Petrus P, Conrad M, Ryden M, Arner ES (2016) Thioredoxin reductase 1 suppresses adipocyte differentiation and insulin responsiveness. Sci Rep 6:28080
pubmed: 27346647
pmcid: 4921861
Poerschke RL, Franklin MR, Bild AH, Moos PJ (2012) Major differences among chemopreventive organoselenocompounds in the sustained elevation of cytoprotective genes. J Biochem Mol Toxicol 26:344–353
pubmed: 22807314
pmcid: 4551423
Poet GJ, Oka OB, van Lith M, Cao Z, Robinson PJ, Pringle MA, Arner ES, Bulleid NJ (2017) Cytosolic thioredoxin reductase 1 is required for correct disulfide formation in the ER. EMBO J 36:693–702
pubmed: 28093500
pmcid: 5331760
Prast-Nielsen S, Cebula M, Pader I, Arner ES (2010) Noble metal targeting of thioredoxin reductase – covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. Free Radic Biol Med 49:1765–1778
pubmed: 20851179
Prast-Nielsen S, Dexheimer TS, Schultz L, Stafford WC, Cheng Q, Xu J, Jadhav A, Arnér ES, Simeonov A (2011) Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay. Free Radic Biol Med 50:1114–1123
pubmed: 21262347
pmcid: 3070820
Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arner ES, Schmidt EE (2012a) Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1. Free Radic Biol Med 52:803–810
pubmed: 22198266
Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arnér ESJ, Schmidt EE (2012b) Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1. Free Radic Biol Med 52:803–810
pubmed: 22198266
Prigge JR, Coppo L, Martin SS, Ogata F, Miller CG, Bruschwein MD, Orlicky DJ, Shearn CT, Kundert JA, Lytchier J, Herr AE, Mattsson A, Taylor MP, Gustafsson TN, Arner ESJ, Holmgren A, Schmidt EE (2017) Hepatocyte hyperproliferation upon liver-specific co-disruption of thioredoxin-1, thioredoxin reductase-1, and glutathione reductase. Cell Rep 19:2771–2781
pubmed: 28658624
pmcid: 5730093
Rackham O, Shearwood AM, Thyer R, McNamara E, Davies SM, Callus BA, Miranda-Vizuete A, Berners-Price SJ, Cheng Q, Arnér ES, Filipovska A (2011) Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: implications for development of specific inhibitors. Free Radic Biol Med 50:689–699
pubmed: 21172426
Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, Jadhav A, Leister W, Shen M, Inglese J, Austin CP, Keefer L, Arner ES, Simeonov A, Maloney DJ, Williams DL, Thomas CJ (2009) Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem 52:6474–6483
pubmed: 19761212
pmcid: 2772170
Reich HJ, Hondal RJ (2016) Why nature chose selenium. ACS Chem Biol 11:821–841
Rhee SG (2006) Cell signaling. H2O2, a necessary evil for cell signaling. Science 312:1882–1883
pubmed: 16809515
Rigobello MP, Callegaro MT, Barzon E, Benetti M, Bindoli A (1998) Purification of mitochondrial thioredoxin reductase and its involvement in the redox regulation of membrane permeability. Free Radic Biol Med 24:370–376
pubmed: 9433913
Rigobello MP, Folda A, Baldoin MC, Scutari G, Bindoli A (2005) Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res 39:687–695
pubmed: 16036347
Roder C, Thomson MJ (2015) Auranofin: repurposing an old drug for a golden new age. Drugs R D 15:13–20
pubmed: 25698589
pmcid: 4359176
Rollins MF, van der Heide DM, Weisend CM, Kundert JA, Comstock KM, Suvorova ES, Capecchi MR, Merrill GF, Schmidt EE (2010) Hepatocytes lacking thioredoxin reductase 1 have normal replicative potential during development and regeneration. J Cell Sci 123:2402–2412
pubmed: 20571049
pmcid: 2894656
Ross F, Hernandez P, Porcal W, Lopez GV, Cerecetto H, Gonzalez M, Basika T, Carmona C, Flo M, Maggioli G, Bonilla M, Gladyshev VN, Boiani M, Salinas G (2012) Identification of thioredoxin glutathione reductase inhibitors that kill cestode and trematode parasites. PLoS One 7:e35033
pubmed: 22536349
pmcid: 3335049
Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462–472
pubmed: 25858805
pmcid: 4400235
Rundlöf A-K, Arnér ESJ (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth and signaling events. Antioxid Redox Signal 6:41–52
pubmed: 14980055
Rundlof AK, Arner ES (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 6:41–52
pubmed: 14980055
Rundlof AK, Carlsten M, Giacobini MM, Arner ES (2000) Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5′ untranslated region. Biochem J 347(Pt 3):661–668
pubmed: 10769168
pmcid: 1221001
Rundlof AK, Janard M, Miranda-Vizuete A, Arner ES (2004) Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic Biol Med 36:641–656
pubmed: 14980707
Rundlof AK, Fernandes AP, Selenius M, Babic M, Shariatgorji M, Nilsonne G, Ilag LL, Dobra K, Bjornstedt M (2007) Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation 75:123–132
pubmed: 17316382
Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, Choi AM (2007) Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 9:49–89
pubmed: 17115887
Saiz C, Castillo V, Fontan P, Bonilla M, Salinas G, Rodriguez-Haralambides A, Mahler SG (2014) Discovering Echinococcus granulosus thioredoxin glutathione reductase inhibitors through site-specific dynamic combinatorial chemistry. Mol Divers 18:1–12
pubmed: 24136658
Sandalova T, Zhong L, Lindqvist Y, Holmgren A, Schneider G (2001) Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci U S A 98:9533–9538
pubmed: 11481439
pmcid: 55487
Schmidt EE (2015) Interplay between cytosolic disulfide reductase systems and the Nrf2/Keap1 pathway. Biochem Soc Trans 43:632–638
pubmed: 26551704
pmcid: 4613508
Shahabi V, Postow MA, Tuck D, Wolchok JD (2015) Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 38:90–97
pubmed: 25616204
Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J, Eriksson S, Hedstrom E, Issaeva N, Kel A, Arner ES, Selivanova G (2014) ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 21:612–623
pubmed: 24413150
pmcid: 3950324
Shukla R, Shukla H, Kalita P, Tripathi T (2018) Structural insights into natural compounds as inhibitors of Fasciola gigantica thioredoxin glutathione reductase. J Cell Biochem 119:3067–3080
Silvestri I, Lyu H, Fata F, Boumis G, Miele AE, Ardini M, Ippoliti R, Bellelli A, Jadhav A, Lea WA, Simeonov A, Cheng Q, Arner ESJ, Thatcher GRJ, Petukhov PA, Williams DL, Angelucci F (2018) Fragment-based discovery of a regulatory site in thioredoxin glutathione reductase acting as "Doorstop" for NADPH entry. ACS Chem Biol 13:2190–2202
pubmed: 29800515
pmcid: 6905387
Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, Thomas CJ, Inglese J, Williams DL, Austin CP (2008) Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis 2:e127
pubmed: 18235848
pmcid: 2217675
Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S (2008) RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68:7975–7984
pubmed: 18829555
pmcid: 3070411
Song L, Li J, Xie S, Qian C, Wang J, Zhang W, Yin X, Hua Z, Yu C (2012) Thioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicum. PLoS One 7:e31456
pubmed: 22384025
pmcid: 3285170
Stafford WC, Peng X, Olofsson MH, Zhang X, Luci DK, Lu L, Cheng Q, Tresaugues L, Dexheimer TS, Coussens NP, Augsten M, Ahlzen HM, Orwar O, Ostman A, Stone-Elander S, Maloney DJ, Jadhav A, Simeonov A, Linder S, Arner ESJ (2018) Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med 10:eaaf7444
Su D, Gladyshev VN (2004) Alternative splicing involving the thioredoxin reductase module in mammals: a glutaredoxin-containing thioredoxin reductase 1. Biochemistry 43:12177–12188
pubmed: 15379556
Su D, Novoselov SV, Sun QA, Moustafa ME, Zhou Y, Oko R, Hatfield DL, Gladyshev VN (2005) Mammalian selenoprotein thioredoxin-glutathione reductase. Roles in disulfide bond formation and sperm maturation. J Biol Chem 280:26491–26498
pubmed: 15901730
Sun QA, Kirnarsky L, Sherman S, Gladyshev VN (2001a) Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci U S A 98:3673–3678
pubmed: 11259642
pmcid: 31110
Sun QA, Zappacosta F, Factor VM, Wirth PJ, Hatfield DL, Gladyshev VN (2001b) Heterogeneity within animal thioredoxin reductases. Evidence for alternative first exon splicing. J Biol Chem 276:3106–3114
pubmed: 11060283
Sun QA, Zappacosta F, Factor VM, Wirth PJ, Hatfield DL, Gladyshev VN (2001c) Heterogeneity within animal thioredoxin reductases. Evidence for alternative first exon splicing. J Biol Chem 276:3106–3114
pubmed: 11060283
Sun QA, Su D, Novoselov SV, Carlson BA, Hatfield DL, Gladyshev VN (2005) Reaction mechanism and regulation of mammalian thioredoxin/glutathione reductase. Biochemistry 44:14528–14537
pubmed: 16262253
Surh YJ, Kundu JK, Na HK (2008) Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 74:1526–1539
pubmed: 18937164
Suvorova ES, Lucas O, Weisend CM, Rollins MF, Merrill GF, Capecchi MR, Schmidt EE (2009) Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS One 4:e6158
pubmed: 19584930
pmcid: 2703566
Tamura T, Stadtman TC (1996) A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci U S A 93:1006–1011
pubmed: 8577704
pmcid: 40020
Tong KI, Kobayashi A, Katsuoka F, Yamamoto M (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 387:1311–1320
pubmed: 17081101
Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241–252
pubmed: 16959615
Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579–591
pubmed: 19478820
Urig S, Becker K (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16:452–465
pubmed: 17056271
Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35(Suppl):S185–S198
pubmed: 25818339
Wang X, Zhang J, Xu T (2008) Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur J Pharmacol 579:66–73
pubmed: 18028906
Williams CH Jr (1992) Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase, and mercuric ion reductase – a family of flavoenzyme transhydrogenases. In: Müller F (ed) Chemistry and biochemistry of flavoenzymes, vol 3. CRC Press, Boca Raton, FL, pp 121–211
Williams DL, Bonilla M, Gladyshev VN, Salinas G (2013) Thioredoxin glutathione reductase-dependent redox networks in platyhelminth parasites. Antioxid Redox Signal 19:735–745
Wipf P, Lynch SM, Birmingham A, Tamayo G, Jimenez A, Campos N, Powis G (2004) Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. Org Biomol Chem 2:1651–1658
pubmed: 15162219
Witte AB, Anestål K, Jerremalm E, Ehrsson H, Arnér ESJ (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39:696–703
pubmed: 16085187
Wondrak GT (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11:3013–3069
pubmed: 19496700
pmcid: 2824519
Woo JR, Kim SJ, Jeong W, Cho YH, Lee SC, Chung YJ, Rhee SG, Ryu SE (2004) Structural basis of cellular redox regulation by human TRP14. J Biol Chem 279:48120–48125
pubmed: 15355959
Xia L, Nordman T, Olsson JM, Damdimopoulos A, Björkhem-Bergman L, Nalvarte I, Eriksson LC, Arnér ESJ, Spyrou G, Björnstedt M (2003) The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J Biol Chem 278:2141–2146
pubmed: 12435734
Yant LJ, Ran Q, Rao L, Van Remmen H, Shibatani T, Belter JG, Motta L, Richardson A, Prolla TA (2003) The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med 34:496–502
pubmed: 12566075
Ye ZW, Zhang J, Townsend DM, Tew KD (2015) Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta 1850:1607–1621
pubmed: 25445706
Ye SF, Li J, Ji SM, Zeng HH, Lu W (2017) Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model. Acta Pharmacol Sin 38:223–232
pubmed: 27917873
Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281:13005–13008
pubmed: 16565519
Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN, Hatfield DL (2007) Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One 2:e1112
pubmed: 17971875
pmcid: 2040202
Zhang DD (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38:769–789
Zhang B, Zhang J, Peng S, Liu R, Li X, Hou Y, Han X, Fang J (2016) Thioredoxin reductase inhibitors: a patent review. Expert Opin Ther Pat:1–10
Zhang B, Liu Y, Li X, Xu J, Fang J (2018) Small molecules to target the selenoprotein thioredoxin reductase. Chem Asian J 13:3593–3600
pubmed: 30204305
Zhang J, Zhang B, Li X, Han X, Liu R, Fang J (2019) Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: an update. Med Res Rev 39:5–39
pubmed: 29727025
Zhao C, Gillette DD, Li X, Zhang Z, Wen H (2014) Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J Biol Chem 289:17020–17029
pubmed: 24798340
pmcid: 4059144
Zhong L, Holmgren A (2000) Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem 275:18121–18128
pubmed: 10849437
Zhong L, Arnér ESJ, Ljung J, Åslund F, Holmgren A (1998) Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J Biol Chem 273:8581–8591
pubmed: 9535831
Zhong L, Arnér ESJ, Holmgren A (2000) Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A 97:5854–5859
pubmed: 10801974
pmcid: 18523